GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Owner Earnings per Share (TTM)

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Owner Earnings per Share (TTM) : 1.64 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

SciClone Pharmaceuticals (Holdings)'s Owner Earnings per Share (TTM) ended in Dec. 2023 was HK$1.64. It's Price-to-Owner-Earnings ratio for today is 11.37.


The historical rank and industry rank for SciClone Pharmaceuticals (Holdings)'s Owner Earnings per Share (TTM) or its related term are showing as below:

HKSE:06600' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.81   Med: 9.25   Max: 17.04
Current: 11.33


During the past 7 years, the highest Price-to-Owner-Earnings ratio of SciClone Pharmaceuticals (Holdings) was 17.04. The lowest was 3.81. And the median was 9.25.


HKSE:06600's Price-to-Owner-Earnings is ranked better than
82.46% of 422 companies
in the Drug Manufacturers industry
Industry Median: 25.585 vs HKSE:06600: 11.33

SciClone Pharmaceuticals (Holdings)'s Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$0.83. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.88. It's PE Ratio ratio for today is 9.91.

SciClone Pharmaceuticals (Holdings)'s EPS without NRI for the six months ended in Dec. 2023 was HK$0.85. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.90. It's PE Ratio without NRI ratio for today is 9.81.


SciClone Pharmaceuticals (Holdings) Owner Earnings per Share (TTM) Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Owner Earnings per Share (TTM) Chart

SciClone Pharmaceuticals (Holdings) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - 1.49 0.87 1.64

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.49 - 0.87 - 1.64

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals (Holdings)'s Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s Price-to-Owner-Earnings falls into.



SciClone Pharmaceuticals (Holdings) Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

SciClone Pharmaceuticals (Holdings)'s Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 1,227
Depreciation, Depletion and Amortization 159
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 221
Change In Working Capital -99
Shares Outstanding (Diluted Average) 650

1. Start with "Net Income" from income statement. SciClone Pharmaceuticals (Holdings)'s Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,227 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. SciClone Pharmaceuticals (Holdings)'s Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was HK$159 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. SciClone Pharmaceuticals (Holdings)'s Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = HK$221 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

SciClone Pharmaceuticals (Holdings)'s 5-Year Average Maintenance Capital Expenditure = HK$221 Mil

5. "Change In Working Capital" is from cashflow statement. SciClone Pharmaceuticals (Holdings)'s Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-99 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. SciClone Pharmaceuticals (Holdings)'s Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 650.433 Mil.

SciClone Pharmaceuticals (Holdings)'s Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 1227.113 +159.161+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-221.3858+-98.548)/650.433
=1.64

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=18.64/1.64
=11.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


SciClone Pharmaceuticals (Holdings) Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Traded in Other Exchanges
N/A
Address
381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Zhao Hong 2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang 2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited 2501 Other
Ascendent Capital Partners Ii Gp Limited 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p. 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p. 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited 2101 Beneficial owner
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Bank Of China Limited 2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited 2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines